Table Graph
      published meta-analysis   sensitivity analysis   studies

dexamethasone in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsRashad, 2021 (REV) 0.35 [0.17; 0.74] Rashad, 2021 0.35 [0.17; 0.74] 0.35[0.21; 0.59]Rashad, 2021 (REV), Rashad, 202120%298seriousnot evaluable deathsdetailed resultsRanjbar, 2021 (REV) 2.50 [0.93; 6.75] Rashad, 2021 (REV) 0.46 [0.24; 0.87] Rashad, 2021 0.46 [0.24; 0.88] 0.75[0.30; 1.87]Ranjbar, 2021 (REV), Rashad, 2021 (REV), Rashad, 2021378%384seriousnot evaluable deaths (time to event analysis only)detailed resultsRashad, 2021 (REV) 0.46 [0.24; 0.87] Rashad, 2021 0.46 [0.24; 0.88] 0.46[0.29; 0.73]Rashad, 2021 (REV), Rashad, 202120%298seriousnot evaluable mechanical ventilationdetailed resultsRanjbar, 2021 (REV) 2.77 [1.03; 7.43] 2.77[1.03; 7.43]Ranjbar, 2021 (REV)10%86NAnot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-05-16 06:11 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 666,1149,1150 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons